Literature DB >> 18166301

Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations.

Bryna Harwood1, Leslie A Meyn, Susan A Ballagh, Elizabeth G Raymond, David F Archer, Mitchell D Creinin.   

Abstract

OBJECTIVE: This study was undertaken to compare the colposcopic appearance of the cervicovaginal epithelium with spermicide use vs condom use in a low-risk population. STUDY
DESIGN: This was an ancillary study of a trial comparing the efficacy of 5 nonoxynol-9 spermicides. A cohort of women who used condoms without spermicide served as a control group. Colposcopic examinations were performed during product use to identify genital lesions.
RESULTS: One hundred fifty-one participants had 1 or more follow-up examinations. At baseline, study groups differed only by the prevalence of baseline lesions. New lesions were identified at 49% of follow-up visits. Controlling for the presence of a baseline lesion, compared with condom use none of the spermicides were associated with an increase in new lesions (overall odds ratio, 0.8; 95% CI, 0.4-1.6; P = .5); and lesions characterized by epithelial disruption were less frequent with spermicide use (overall odds ratio, 0.3; 95% CI, 0.1-0.6; P < .001).
CONCLUSION: In a low-risk population, women who used nonoxynol-9 spermicides were less likely to have lesions with epithelial disruption, and equally likely to have any new lesion compared with condom use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18166301      PMCID: PMC4332520          DOI: 10.1016/j.ajog.2007.05.020

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

Review 1.  Contraceptive failure in the United States.

Authors:  James Trussell
Journal:  Contraception       Date:  2004-08       Impact factor: 3.375

2.  Effects of long-term use of nonoxynol-9 on vaginal flora.

Authors:  Courtney A Schreiber; Leslie A Meyn; Mitchell D Creinin; Kurt T Barnhart; Sharon L Hillier
Journal:  Obstet Gynecol       Date:  2006-01       Impact factor: 7.661

3.  A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy.

Authors:  C K Mauck; J M Baker; S P Barr; T J Abercrombie; D F Archer
Journal:  Contraception       Date:  1997-08       Impact factor: 3.375

4.  Unintended pregnancy in the United States.

Authors:  S K Henshaw
Journal:  Fam Plann Perspect       Date:  1998 Jan-Feb

5.  The effects of three nonoxynol-9 preparations on vaginal flora and epithelium.

Authors:  D H Watts; L Rabe; M A Krohn; J Aura; S L Hillier
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

6.  Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.

Authors:  M K Stafford; H Ward; A Flanagan; I J Rosenstein; D Taylor-Robinson; J R Smith; J Weber; V S Kitchen
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-04-01

7.  Safety and tolerability of the new contraceptive sponge Protectaid.

Authors:  G Creatsas; A Elsheikh; P Colin
Journal:  Eur J Contracept Reprod Health Care       Date:  2002-06       Impact factor: 1.848

8.  The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa.

Authors:  S Niruthisard; R E Roddy; S Chutivongse
Journal:  Sex Transm Dis       Date:  1991 Jul-Sep       Impact factor: 2.830

9.  Mucosal disruption due to use of a widely-distributed commercial vaginal product: potential to facilitate HIV transmission.

Authors:  P H Kilmarx; K Limpakarnjanarat; S Supawitkul; S Korattana; N L Young; B S Parekh; R A Respess; T D Mastro; M E St Louis
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

10.  Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial.

Authors:  Elizabeth G Raymond; Pai Lien Chen; Joanne Luoto
Journal:  Obstet Gynecol       Date:  2004-03       Impact factor: 7.661

View more
  2 in total

1.  Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides.

Authors:  H Irene Su; Courtney A Schreiber; Courtney Fay; Sam Parry; Michal A Elovitz; Jian Zhang; Alka Shaunik; Kurt Barnhart
Journal:  Contraception       Date:  2011-03-29       Impact factor: 3.375

2.  In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.

Authors:  Lisa C Rohan; Bernard J Moncla; Ratiya Pamela Kunjara Na Ayudhya; Marilyn Cost; Yunda Huang; Fang Gai; Nicole Billitto; J D Lynam; Kara Pryke; Phillip Graebing; Nicole Hopkins; James F Rooney; David Friend; Charlene S Dezzutti
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.